Australian biotech HaemaLogiX spoke to Scrip about its approach to the multiple myeloma space, and how it differentiates itself with new drug targets.

“There are a lot of drugs for multiple myeloma. It’s, in some ways, a very crowded space,” said CEO Chris Baldwin. “But we’re the only ones who are targeting KMA/LMA. Part of that is due to the extensive patent portfolio that we’ve established and developed over the course of the last 20 years. It means that when we come into the market, we have a very strong differentiator compared to anything out there,” Baldwin continued.

Read the full story here.